{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T22:59:36Z","timestamp":1789340376710,"version":"build-2803163510"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,6,3]],"date-time":"2018-06-03T00:00:00Z","timestamp":1527984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"funder":[{"DOI":"10.13039\/501100006506","name":"Brazilian Ministry of Health","doi-asserted-by":"publisher","award":["TC 235\/2012"],"award-info":[{"award-number":["TC 235\/2012"]}],"id":[{"id":"10.13039\/501100006506","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI077505, AI069439"],"award-info":[{"award-number":["AI077505, AI069439"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["TR002243"],"award-info":[{"award-number":["TR002243"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1093\/jac\/dky190","type":"journal-article","created":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T06:46:59Z","timestamp":1524811619000},"page":"2460-2467","source":"Crossref","is-referenced-by-count":19,"title":["Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals"],"prefix":"10.1093","volume":"73","author":[{"given":"Tailah Bernardo","family":"de Almeida","sequence":"first","affiliation":[{"name":"Laborat\u00f3rio de Virologia Molecular, Departamento de Gen\u00e9tica, Instituto de Biologia, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Costa Velho Mendes","family":"de Azevedo","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio Gaffr\u00e9e e Guinle, Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Francisco da Cunha","family":"Pinto","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio Gaffr\u00e9e e Guinle, Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Rafael de Almeida","family":"Ferry","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio Gaffr\u00e9e e Guinle, Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Almeida Rosa","family":"da Silva","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio Gaffr\u00e9e e Guinle, Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izana Junqueira","family":"de Castro","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio Gaffr\u00e9e e Guinle, Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paxton","family":"Baker","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Medicine, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amilcar","family":"Tanuri","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Virologia Molecular, Departamento de Gen\u00e9tica, Instituto de Biologia, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Haas","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Medicine, Nashville, TN, USA"},{"name":"Meharry Medical College, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia C","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Virologia Molecular, Departamento de Gen\u00e9tica, Instituto de Biologia, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,3]]},"reference":[{"key":"key\n\t\t\t\t20180823025348_dky190-B1","author":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)","year":"2017"},{"key":"key\n\t\t\t\t20180823025348_dky190-B2","author":"WHO","year":"2016"},{"key":"key\n\t\t\t\t20180823025348_dky190-B3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1590\/S1413-86702007000100007","article-title":"Self-reported adverse reactions among patients initiating antiretroviral therapy in Brazil","volume":"11","author":"P\u00e1dua","year":"2007","journal-title":"Braz J Infect Dis"},{"key":"key\n\t\t\t\t20180823025348_dky190-B4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1413-8670(12)70270-2","article-title":"Durability of the first combined antiretroviral regimen in patients with AIDS at a reference center in Belo Horizonte, Brazil, from 1996 to 2005","volume":"16","author":"Ribeiro","year":"2012","journal-title":"Braz J Infect Dis"},{"key":"key\n\t\t\t\t20180823025348_dky190-B5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3109\/00365548.2013.773067","article-title":"Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects","volume":"45","author":"Leutscher","year":"2013","journal-title":"Scand J Infect Dis"},{"key":"key\n\t\t\t\t20180823025348_dky190-B6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180823025348_dky190-B7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity","volume":"306","author":"Ward","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20180823025348_dky190-B8","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1124\/dmd.109.031393","article-title":"Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation","volume":"38","author":"Ogburn","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t20180823025348_dky190-B9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrd753","article-title":"PXR, CAR and drug metabolism","volume":"1","author":"Willson","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t20180823025348_dky190-B10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3109\/00498254.2011.551849","article-title":"Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites","volume":"41","author":"Bae","year":"2011","journal-title":"Xenobiotica"},{"key":"key\n\t\t\t\t20180823025348_dky190-B11","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1124\/dmd.109.027706","article-title":"Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine","volume":"37","author":"B\u00e9langer","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t20180823025348_dky190-B12","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180823025348_dky190-B13","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1097\/QAD.0b013e3283319908","article-title":"CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients","volume":"23","author":"Kwara","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180823025348_dky190-B14","doi-asserted-by":"crossref","first-page":"112.","DOI":"10.1186\/1471-2350-13-112","article-title":"PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV\/AIDS patients","volume":"13","author":"Swart","year":"2012","journal-title":"BMC Med Genet"},{"key":"key\n\t\t\t\t20180823025348_dky190-B15","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1093\/jac\/dku110","article-title":"Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes","volume":"69","author":"Haas","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180823025348_dky190-B16","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2004.05.116","article-title":"Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens","volume":"319","author":"Tsuchiya","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"key\n\t\t\t\t20180823025348_dky190-B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"key\n\t\t\t\t20180823025348_dky190-B18","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/497610","article-title":"Pharmacogenetics of long\u2010term responses to antiretroviral regimens containing efavirenz and\/or nelfinavir: an Adult AIDS Clinical Trials Group study","volume":"192","author":"Haas","year":"2005","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180823025348_dky190-B19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.tpj.6500374","article-title":"Overview of the pharmacogenetics of HIV therapy","volume":"6","author":"Rodr\u00edguez-N\u00f3voa","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"key\n\t\t\t\t20180823025348_dky190-B20","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/FPC.0b013e32835a450b","article-title":"Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants","volume":"22","author":"Holzinger","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"key\n\t\t\t\t20180823025348_dky190-B21","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn029","article-title":"Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients","volume":"61","author":"Wyen","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180823025348_dky190-B22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/655470","article-title":"Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study","volume":"202","author":"Ribaudo","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180823025348_dky190-B23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0140-6736(02)07276-8","article-title":"Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetic study","volume":"359","author":"Fellay","year":"2002","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180823025348_dky190-B24","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2217\/pgs.10.94","article-title":"Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients","volume":"11","author":"Elens","year":"2010","journal-title":"Pharmacogenomics"},{"key":"key\n\t\t\t\t20180823025348_dky190-B25","doi-asserted-by":"crossref","first-page":"e67946.","DOI":"10.1371\/journal.pone.0067946","article-title":"Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations","volume":"8","author":"Ngaimisi","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180823025348_dky190-B26","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fgene.2012.00236","article-title":"ABCB1 4036A>G and 1236C>T polymorphisms affect plasma efavirenz levels in South African HIV\/AIDS patients","volume":"3","author":"Swart","year":"2012","journal-title":"Front Genet"},{"key":"key\n\t\t\t\t20180823025348_dky190-B27","doi-asserted-by":"crossref","first-page":"261.","DOI":"10.1186\/1471-2334-13-261","article-title":"Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study","volume":"13","author":"Mukonzo","year":"2013","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180823025348_dky190-B28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1742-6405-7-32","article-title":"Presence of the CYP2B6 516G>T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients","volume":"7","author":"Gounden","year":"2010","journal-title":"AIDS Res Ther"},{"key":"key\n\t\t\t\t20180823025348_dky190-B29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fphar.2010.00118","article-title":"Pharmacogenetics in the Brazilian population","volume":"1","author":"Suarez-Kurtz","year":"2010","journal-title":"Front Pharmacol"},{"key":"key\n\t\t\t\t20180823025348_dky190-B30","doi-asserted-by":"crossref","first-page":"e0163170.","DOI":"10.1371\/journal.pone.0163170","article-title":"Single nucleotide polymorphisms in cellular drug transporters are associated with intolerance to antiretroviral therapy in Brazilian HIV-1 positive individuals","volume":"11","author":"Arruda","year":"2016","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180823025348_dky190-B31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajhb.20976","article-title":"Genetic composition of Brazilian population samples based on a set of twenty-eight ancestry informative SNPs","volume":"22","author":"Lins","year":"2010","journal-title":"Am J Hum Biol"},{"key":"key\n\t\t\t\t20180823025348_dky190-B32","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/genetics\/155.2.945","article-title":"Inference of population structure using multilocus genotype data","volume":"155","author":"Pritchard","year":"2000","journal-title":"Genetics"},{"key":"key\n\t\t\t\t20180823025348_dky190-B33","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/genetics\/164.4.1567","article-title":"Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies","volume":"164","author":"Falush","year":"2003","journal-title":"Genetics"},{"key":"key\n\t\t\t\t20180823025348_dky190-B34","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1471-8286.2007.01758.x","article-title":"Inference of population structure using multilocus genotype data: dominant markers and null alleles","volume":"7","author":"Falush","year":"2007","journal-title":"Mol Ecol Notes"},{"key":"key\n\t\t\t\t20180823025348_dky190-B35","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/j.1755-0998.2009.02591.x","article-title":"Inferring weak population structure with the assistance of sample group information","volume":"9","author":"Hubisz","year":"2009","journal-title":"Mol Ecol Resour"},{"key":"key\n\t\t\t\t20180823025348_dky190-B36","doi-asserted-by":"crossref","first-page":"e75145.","DOI":"10.1371\/journal.pone.0075145","article-title":"Revisiting the genetic ancestry of Brazilians using autosomal AIM-Indels","volume":"8","author":"Saloum de Neves Manta","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180823025348_dky190-B37","author":"R Development Core Team","year":"2011"},{"key":"key\n\t\t\t\t20180823025348_dky190-B38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1590\/0001-3765201720160355","article-title":"CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under efavirenz treatment: study of a sample from southern Brazil","volume":"89","author":"M\u00fcller","year":"2017","journal-title":"An Acad Bras Ci\u00eanc"},{"key":"key\n\t\t\t\t20180823025348_dky190-B39","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/jcph.165","article-title":"ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in northeast Brazil patients","volume":"53","author":"Coelho","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180823025348_dky190-B40","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s13365-015-0382-7","article-title":"Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients","volume":"22","author":"Ma","year":"2016","journal-title":"J Neurovirol"},{"key":"key\n\t\t\t\t20180823025348_dky190-B41","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/0003-4819-143-10-200511150-00008","article-title":"Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals","volume":"143","author":"Clifford","year":"2005","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180823025348_dky190-B42","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/infdis\/jix248","article-title":"Race\/ethnicity and the pharmacogenetics of reported suicidality with efavirenz among clinical trials participants","volume":"216","author":"Mollan","year":"2017","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180823025348_dky190-B43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/FPC.0000000000000238","article-title":"Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race","volume":"26","author":"Leger","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"key\n\t\t\t\t20180823025348_dky190-B44","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1124\/pr.111.005553","article-title":"The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition","volume":"64","author":"Michaud","year":"2012","journal-title":"Pharmacol Rev"},{"key":"key\n\t\t\t\t20180823025348_dky190-B45","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/clpt.2008.271","article-title":"Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals","volume":"85","author":"Arab-Alameddine","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180823025348_dky190-B46","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1023\/A:1016430825740","article-title":"Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture","volume":"19","author":"Stormer","year":"2002","journal-title":"Pharm Res"},{"key":"key\n\t\t\t\t20180823025348_dky190-B47","doi-asserted-by":"crossref","first-page":"e46295","DOI":"10.1371\/journal.pone.0046295","article-title":"Gene-wide characterization of common quantitative trait loci for ABCB1 mRNA expression in normal liver tissues in the Chinese population","volume":"7","author":"Shou","year":"2012","journal-title":"PLoS One"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/9\/2460\/25523132\/dky190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T10:08:21Z","timestamp":1720260501000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/9\/2460\/5032554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,3]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,6,3]]},"published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky190","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9]]},"published":{"date-parts":[[2018,6,3]]}}}